Steis RG - Search Results

1

The determination of an immunologically active dose of interferon-gamma in patients with melanoma.

Maluish AE, Urba WJ, Longo DL, Overton WR, Coggin D, Crisp ER, Williams R, Sherwin SA, Gordon K, Steis RG. Maluish AE, et al. Among authors: steis rg. J Clin Oncol. 1988 Mar;6(3):434-45. doi: 10.1200/JCO.1988.6.3.434. J Clin Oncol. 1988. PMID: 3127550

2

The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies.

Smith JW 2nd, Urba WJ, Curti BD, Elwood LJ, Steis RG, Janik JE, Sharfman WH, Miller LL, Fenton RG, Conlon KC, et al. Smith JW 2nd, et al. Among authors: steis rg. J Clin Oncol. 1992 Jul;10(7):1141-52. doi: 10.1200/JCO.1992.10.7.1141. J Clin Oncol. 1992. PMID: 1607919 Clinical Trial.

3

Phase I evaluation of recombinant tumor necrosis factor given in combination with recombinant interferon-gamma.

Smith JW 2nd, Urba WJ, Clark JW, Longo DL, Farrell M, Creekmore SP, Conlon KC, Jaffe H, Steis RG. Smith JW 2nd, et al. Among authors: steis rg. J Immunother (1991). 1991 Oct;10(5):355-62. doi: 10.1097/00002371-199110000-00007. J Immunother (1991). 1991. PMID: 1790143 Clinical Trial.

4

The in vivo immunomodulatory effects of recombinant interferon gamma plus recombinant tumor necrosis factor-alfa.

Urba WJ, Kopp WC, Clark JW, Smith JW 2nd, Steis RG, Huber C, Coggin D, Longo DL. Urba WJ, et al. Among authors: steis rg. J Clin Oncol. 1991 Oct;9(10):1831-9. doi: 10.1200/JCO.1991.9.10.1831. J Clin Oncol. 1991. PMID: 1919633 Clinical Trial.

5

Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer.

Urba WJ, Steis RG, Longo DL, Kopp WC, Maluish AE, Marcon L, Nelson DL, Stevenson HC, Clark JW. Urba WJ, et al. Among authors: steis rg. Cancer Res. 1990 Jan 1;50(1):185-92. Cancer Res. 1990. PMID: 2293554

6

Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndrome.

Kohn EC, Steis RG, Sausville EA, Veach SR, Stocker JL, Phelps R, Franco S, Longo DL, Bunn PA, Ihde DC. Kohn EC, et al. Among authors: steis rg. J Clin Oncol. 1990 Jan;8(1):155-60. doi: 10.1200/JCO.1990.8.1.155. J Clin Oncol. 1990. PMID: 2295906

7

Treatment of hairy cell leukemia with alternating cycles of pentostatin and recombinant leukocyte A interferon: results of a phase II study.

Martin A, Nerenstone S, Urba WJ, Longo DL, Lawrence JB, Clark JW, Hawkins MJ, Creekmore SP, Smith JW 2nd, Steis RG. Martin A, et al. Among authors: steis rg. J Clin Oncol. 1990 Apr;8(4):721-30. doi: 10.1200/JCO.1990.8.4.721. J Clin Oncol. 1990. PMID: 2313337

8

Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanoma.

Miller RL, Steis RG, Clark JW, Smith JW 2nd, Crum E, McKnight JE, Hawkins MJ, Jones MJ, Longo DL, Urba WJ. Miller RL, et al. Among authors: steis rg. Cancer Res. 1989 Apr 1;49(7):1871-6. Cancer Res. 1989. PMID: 2647294 Clinical Trial.

9

Dose-related immunologic effects of levamisole in patients with cancer.

Janik J, Kopp WC, Smith JW 2nd, Longo DL, Alvord WG, Sharfman WH, Fenton RG, Sznol M, Steis RG, Creekmore SP, et al. Janik J, et al. Among authors: steis rg. J Clin Oncol. 1993 Jan;11(1):125-35. doi: 10.1200/JCO.1993.11.1.125. J Clin Oncol. 1993. PMID: 8418223 Clinical Trial.

10

Immunomodulatory effects of interferon-gamma in patients with metastatic malignant melanoma.

Kopp WC, Smith JW 2nd, Ewel CH, Alvord WG, Main C, Guyre PM, Steis RG, Longo DL, Urba WJ. Kopp WC, et al. Among authors: steis rg. J Immunother Emphasis Tumor Immunol. 1993 Apr;13(3):181-90. doi: 10.1097/00002371-199304000-00005. J Immunother Emphasis Tumor Immunol. 1993. PMID: 8471592 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

79 results

Search Page